I also believe it was a HUGE tell that the Chief Science Officer (Dr. Alkon) discussed in detail the science of Bryostatin and the 3 compassionate use patients.
If the CEO had presented info about these patients, it wouldn't have the strength of the CSO talking about these 3 patients in glowing terms of recovery.
Dr. Alkon is a 30-year research veteran of the NIH and I don't believe he would present information on patients that isn't backed by objective testing and observation.
News 
Market Data 
Discover 
